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Pharmaceutical companies incorporate different features into the trials for new drug applications (NDAs) to render
them efficient, making use of their experience. The objective of this analysis was to examine the associations
between outcome and features related to study design and clinical development experience in commercially
sponsored clinical trials.
We collected data of phase 2 and phase 3 trials of all the drugs that obtained approval for depression,
schizophrenia, asthma, hypertension, and diabetes in Japan from 1970 to 2011. In total, 145 trials from 90 test drugs
were eligible for our study. We calculated the effect size, the standard mean of differences between test drug and
comparator therapeutic effects, as the objective variable for use in our analysis. A linear mixed effect model with
nested and crossed random effects was used in the analysis including variety of therapeutic area, test drugs and
clinical trials.
The analysis showed that trial features including sample size, subjective endpoints and active comparator of the
same mode of action were negatively associated with effect size. In addition, sponsors’ domestic clinical
development experience with similar drugs seemed to have a positive association, but prior development
experience in foreign countries did not. The accumulation of skills and knowledge within sponsors, and
accumulated experience in domestic professionals who implement clinical trials under study contracts with
sponsors would be of great importance for yielding clear outcomes.
This study provides additional evidence with respect to possible sizes and directions of the influence of study
design features that must be considered when planning and implementing trials for new drug applications, and
when retrospectively comparing outcomes from trials with different designs and environments.
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It has been suggested that recent stagnation in drug
development is related to both a decrease in the prob-
ability of success, and an increase in the costs of re-
search and development (Pammolli et al. 2011). This has
led pharmaceutical companies and even regulatory agen-
cies to address urgent priorities, in an effort to halt this
decline in the rates of successful clinical development.
Conducting well-designed clinical trials and obtaining
positive results are necessary for the approval of a new* Correspondence: shun-ono@mol.f.u-tokyo.ac.jp
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in any medium, provided the original work is pdrug. In commercially sponsored clinical trials, it is
pharmaceutical companies that make decisions on key
components of study design, to achieve their goals most
efficiently within their practical constraints. Previous
studies have indicated that clinical trial outcomes can be
affected by design components such as the number of
treatment arms, sample size, the probability of receiving
a placebo, year of publication, baseline severity of dis-
ease, and dose regimen (Khan et al. 2004; Papakostas
and Fava 2009; Kirsch et al. 2008). These studies mainly
targeted clinical trials in psychiatry with subjective effi-
cacy endpoints; trials with objective endpoints in other
therapeutic fields have not been reviewed intensively.is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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behaviors may also have a substantial impact on study out-
comes (Lundh et al. 2012). Pharmaceutical companies are
usually interested in generating evidence to support clin-
ical efficacy and safety at the minimum cost and burden,
which often depends on their experience, and their choice
of strategy. In this global development era, global compan-
ies can choose the region in which they initiate clinical de-
velopment and submit NDAs first, after assessing the
likelihood of success, costs, and future profits. Preceding
drug development experience in one region will contribute
to subsequent development in other regions. In addition
to global development pathways, domestic development
experience with regard to similar drugs seems to affect the
design and conduct of clinical trials, through the experi-
ence of companies as well as investigators and institutions.
However, previous studies have not sufficiently investi-
gated such aspects of experience.
The aim of the present study was to analyze in what way
study design features and development experience were
associated with the effect size of trial outcomes in both
placebo and active-controlled clinical trials for depression,
schizophrenia, hypertension, asthma, and diabetes drugs.
Many of the previous studies were focused on specific
therapeutic areas, anti-depressant trials in particular (Khan
et al. 2004; Papakostas and Fava 2009; Kirsch et al. 2008;
Rutherford et al. 2009; Rief et al. 2009). Samples of clinical
trials targeted in previous research were collected mainly
from the international clinical trial databases, and were
composed of both commercial and investigator-initiated
trials. In this study, we aimed at commercial trials that
were part of the NDA clinical data package in Japan, and
investigated possible associations between the trial out-
come and relevant factors. This made it possible for us to
establish and test research hypotheses on drug companies’
behaviors, based on data from various phases of clinical
trials for different statistical purposes. Associations be-
tween clinical trials with common attributes (e.g., trials for
the same test drug in different phases) were assessed via a
nested random variable structure as explained in the
Methods section below. We analyzed several types of end-
points and clinical trials, including physical endpoints and




We collected clinical trial data from phase 2 and phase 3
randomized double-blind comparative trials of all the
drugs that obtained approval for depression, schizophre-
nia, asthma, hypertension, and diabetes as new molecu-
lar entities or new indications in Japan from 1970 to
April 2011. All pivotal phase 3 trials and phase 2 trials
that determined final dose and regimen were includedregardless of their outcomes. For some drugs including
escitalopram and ketotifen, clinical trials that did not
achieve pre-determined objectives were included in the
database. For the NDA of duloxetine the first NDAs
were rejected by the authority because of failure to es-
tablish efficacy, and the second NDAs were submitted
with additional confirmatory trials. We chose these
therapeutic fields in order to evaluate the possible im-
pact of endpoint choices, some of which were objective
and others subjective, phases of clinical trials, statistical
purposes such as examining superiority, non-inferiority
and equivalence, types of comparators (placebo or active
comparator), and the use of clinical global impression of
improvement (CGI-I).
Data were extracted from common technical documents
posted on the Japanese regulatory agency (the Pharma-
ceutical and Medical Devices Agency) site (http://www.
info.pmda.go.jp/), from the interview forms, which are
unique to Japan, from pharmaceutical company’s websites,
and from publications on clinical trials conducted for
NDAs (Additional file 1: Table S1). We determined a
pairing of the test drug and a comparator for each trial. In
the case of three-armed trials with a test drug, active con-
trol, and placebo, we assessed two pairs; i.e., the test drug
and the active control, and the test drug and the placebo
and adjusted their possible associations in the nested
random-effect model.
Effect size
Differences between test drug and comparator thera-
peutic effects were calculated using Hedges' adjusted g
for continuous endpoints. Therapeutic effect was defined
as the overall change from baseline to final assessment.
Standard deviation values were not reported in 2 of 145
clinical trials. The values were imputed from the stand-
ard deviation of the other trials with the same endpoint
by using the mean imputation method (Leucht et al.
2009). The sign and size of coefficients in a multi-level
regression model was robust even if we removed the
data of these two clinical trials from our dataset. CGI-I
scale scores that corresponded to moderate clinical im-
provement or greater at the final visit were regarded as
effective, and others were regarded as ineffective. We ap-
plied phi coefficients for CGI-I as effect sizes. For trials
with more than one test drug dose arm, we selected dose
arms within a range of approved standard maintenance
daily dose, and calculated the mean effect size of those
dose arm comparator pairs. Approved maintenance daily
dose was defined as approved dose excluding the dose
only used in titration period.
Effect sizes are under influence of many factors and
interactions thereof in both planning and conducting
stages, including agreement with regulators, efficacy of a
drug per se, alpha and beta risks (i.e., power) set at the
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and quality of conduct. The effect size also satisfies the
following statistical equation by definition;
T ¼ f Nð Þ  g ESð Þ
where T is the test statistic, N is the sample size, ES is
the effect size, and f (.) and g (.) are some function
forms. It should be noted that if there is some constraint
on T (e.g., pre-determined levels of alpha and beta risks),
as is in most late phase trials, ES and N could show
spurious negative association reflecting this statistical re-
lationship. The purpose of this analysis was to explore
possible associations between the effect size and several
observable attributes of clinical trials and provide add-
itional clues to historical discussions on how critical
study design components and company attributes could
affect study outcomes.
Statistical analysis
The differences in effect size across diseases were tested
using the Kruskal-Wallis one-way analysis of variance by
ranks and two-sample t test with equal variances.
We constructed a multi-level regression model with ef-
fect size as the objective variable, whose nested structure
was basically similar to those of previous studies (Hedeker
et al. 1994). A linear mixed effect model with nested and
crossed random effects was used in this analysis. We
expanded a construction of random effects in previous
studies (Rutherford et al. 2009; Woods et al. 2005), as it
seemed reasonable to assume that effect sizes of test drugs
within the disease were correlated and that effect sizes of
trials within a test drug were also correlated. Diseases, test
drugs, and trials were treated as hierarchical random ef-
fects, which enabled to accommodate the nested structure
of subjects within trials within test drugs clustered by dis-
eases. We treated comparators as a crossed random effect
with test drugs because there were multiple pairs of a test
drug and several comparators, and vice versa. The form of
the model was as follows:
Y ijkl ¼ β0 þ β1x1jkl þ…þ βijklxijkl þ ζ i þ ζ ij þ ζ ijk
þ ζ l þ ɛijkl
Yijkl: effect size, xijkl: covariates, ζ: random effects, i:
disease, j: test drug, k: trial, l: comparator.
We adopted four regression models: Models 1 and 3
with explanatory variables related to study design, and
Models 2 and 4 with clinical development variables (i.e.,
precedent foreign clinical trial data and companies’ do-
mestic development experience with similar drugs) in
addition to the variables in Model 1 or 3. Models 3 and
4 were for subgroup analyses with the dataset including
only phase 3 trials, using the same regression model as
Models 1 and 2 except the phase 2 dummy variable.Weclassified a company as having had (or shared, at least)
precedent development experience in foreign countries
in cases where the company submitted foreign clinical
trials in the Japanese NDA. A company was classified as
having had domestic development experience with simi-
lar drugs in cases where it had gained at least one drug
approval for the same therapeutic indication in Japan be-
fore the approval of the drug we analyzed. The signifi-
cance level was set at p < 0.1 as in previous studies
(Hirai et al. 2012). The analysis was performed using
Stata12 (StataCorp, College Station, TX).
Results
Distribution of effect size
In total, 145 trials from 90 test drugs were eligible for in-
clusion in our study. Descriptive data relating to the col-
lected variables are shown in Table 1. The 145 trials
consisted of 33 depression, 25 schizophrenia, 27 asthma,
38 hypertension, and 22 diabetes trials. There were 44
pairs of a test drug and a placebo, and 150 pairs of a test
drug and an active comparator. Effect sizes ranged from
-0.64 to 1.94, and the average was 0.19. Fifty one of 55
negative effect sizes were observed in active-controlled
trials. Other 4 negative effect size were observed in
placebo-controlled trials for depression (duloxetine and
escitalopram) and for bronchial asthma (ketotifen and tra-
nilast), although the trial of tranilast was not considered to
be failed because a favorable result was shown in the pri-
mary endpoint, CGI-I. The mean effect sizes of failed and
successful trials in the NDAs of duloxetine, escitalopram
and ketotifen were -0.020 and 0.164, respectively. Table 1
summarizes the characteristics of collected clinical trials.
A box-whisker plot of effect size by disease is shown in
Figure 1. Effect sizes were significantly different across
diseases (a test drug-placebo pair: p = 0.0001, a test drug-
active comparator pair: p = 0.0001). Further, we found
a statistically significant difference in the means of
effect size between diabetes drugs and non-diabetes
drugs (p < 0.0001).
The mean effect size in diabetes was much larger than
those in other indications (diabetes: 0.48, other indica-
tions: 0.04-0.17). Larger mean effect sizes in diabetes
were observed clearly even in the pairs with active-
control drugs (diabetes: 0.35, other indications: 0.03-
0.12). Negative effect sizes were observed for some trials,
which reflected the fact that there were both successful
and failed trials included in the data packages of success-
fully approved drugs.
Regression analysis
The results of the regression analysis are summarized in
Table 2. The analysis indicated that approval year, super-
iority trials, and primary endpoints were positively asso-
ciated with effect sizes (Model 1). Sample size, subjective
Table 1 Summary statistics of explanatory variables and
effect sizes
Variable n %
Total number of test drug-comparator pairs observed 194 100
Endpoint HDRS 19 10
PANSS 12 6
PEF 16 8
Blood pressure 41 21
HbA1c 24 12
CGI-I Depression 33 17
Schizophrenia 25 13
Asthma 24 12
Comparator Placebo 44 23
Active 150 77




Dose response 20 10
Other 85 44




All 194 2.40 (0.729)a
Sample size 194 236 (108)a
Length of trial (weeks) 194 8.54 (4.10)a
Mean number of subjects
per site
182 5.14 (3.20)a
Approval year 194 1999b
Dosing schedule Flexible 109 56
Fixed 85 44
Type of endpoint Subjective endpoint
(assessment score)
30 15
Subjective endpoint 84 43
(Clinical Global
Improvement)










Table 1 Summary statistics of explanatory variables and
effect sizes (Continued)
Variable n %
Precedent foreign clinical trial data
Yes 83 43
No 111 57
Companies' domestic development experience with similar drugs
Yes 91 47
No 103 53
Mean age of subjects 193 48.0 (7.63)a
Ratio of female subjects 194 0.47 (0.10)a
Effect size Placebo 44 0.58 (0.52)a
Active 150 0.08 (0.22)a
aMean (SD), bMedian.
Precedent foreign clinical data: a dummy variable that was assigned a value of
1 if foreign clinical trials were included in the clinical data package.
Companies’ domestic development experience with similar drugs: a dummy
variable that was assigned a value of 1 when a company had gained at least
one drug approval for the same therapeutic indication in Japan before the
approval of a drug we analyzed.
HDRS: the Hamilton Depression Rating Scale for depression, PNASS: Positive
and Negative Syndrome Scale for schizophrenia, PEF: morning Peak Expiratory
Flow for asthma, Blood pressure: diastolic pressure for hypertension, HbA1c:
hemoglobin A1c for diabetes, CGI-I: Clinical Global Impression of Improvement.
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Depression Rating Scale for depression, Positive and
Negative Syndrome Scale for schizophrenia), subjective
endpoint evaluated with CGI-I, the same mode of action
of the study drug and the active comparator, and the pro-
portion of female subjects were negatively associated with
effect size (Model 1). Among trials with different statistical
purposes, superiority trials were positively correlated with
effect size (b = 0.245, 90% confidence interval 0.115-0.375,
p = 0.002). This result was predictable because most of the
superiority trials were placebo-controlled trials and our
dataset was composed of trials for NDAs that were suc-
cessfully approved.
Companies’ domestic development experience in Japan
with similar drugs was positively associated with effect
size in Model 2 (b = 0.079, 90% confidence interval
0.005-0.153, p = 0.078), but previous experience of for-
eign development was not. We conducted subgroup ana-
lysis of only phase 3 trials using the same regression
model except phase 2 dummy variable. The results are
shown as Models 3 and 4 in Table 2. Precedent foreign
experience as well as companies’ domestic development
experience with similar drugs was positively associated
with effect size in phase 3 trials (b = 0.167; 90% confi-
dence interval 0.041-0.293, p = 0.029).
The random effects variance estimates for the mixed
effect model (Model 1) are 0.019 for diseases, 0.008 for
test drugs, 0.014 for trials, and 0.018 for residuals. These
random effects accounted for 69% of the total residual
variance. As the total residual variance was 0.106 for a
Figure 1 Box-whisker plot of effect sizes of each disease. Gray box: observed effect sizes, white box: predicted effect sizes, AC: effect size of
the pairing of a test drug and an active comparator, P: effect size of the pairing of a test drug and placebo. The boxes show interquartile ranges.
The horizontal line across each box denotes the median, and vertical lines extending above and below each box indicate the minimum and
maximum values. Dots above and below the boxes are outliers.
Table 2 Mixed effect regression analysis of effect sizes
Model 1 (N = 182) Model 2 (N = 182) Model 3 (N = 149) Model 4 (N = 149)
Estimate P value Estimate P value Estimate P value Estimate P value
Number of arms 0.070 0.102 0.055 0.208 0.073 0.282 0.077 0.241
Sample size −0.001 0.007*** −0.001 0.008*** −0.001 0.002*** −0.001 0.000***
Length of trial 0.004 0.495 0.002 0.697 0.003 0.593 0.000 0.957
Flexible dosing schedule −0.072 0.190 −0.070 0.205 −0.098 0.062* −0.112 0.030**
Approval year 0.007 0.028** 0.004 0.307 0.005 0.166 0.000 0.979
Mean number of subjects per site 0.009 0.147 0.007 0.219 0.011 0.065* 0.008 0.171




−0.138 0.022** −0.119 0.048** −0.090 0.136 −0.067 0.263
Subjective endpoint (Clinical Global
Improvement)
−0.115 0.033** −0.094 0.081* −0.076 0.190 −0.049 0.395
Statistical purpose (Othersa) Superiority 0.245 0.002*** 0.215 0.009*** 0.287 0.000*** 0.229 0.005***
Noninferiority and equivalence −0.005 0.933 −0.028 0.700 0.012 0.853 −0.055 0.447
Dose response 0.133 0.269 0.124 0.304 - - - -
Primary endpoint 0.095 0.018** 0.086 0.032** 0.061 0.152 0.050 0.234
Comparator with the same mode of action of the test drug −0.127 0.018** −0.143 0.006*** −0.083 0.124 −0.129 0.020**
Phase2 −0.067 0.384 −0.059 0.447 - - - -
Mean age of subjects 0.006 0.142 0.008 0.075* 0.013 0.004*** 0.015 0.001***
Proportion of female subjects −0.417 0.053* −0.453 0.037** −0.752 0.002*** −0.682 0.004***
Precedent foreign clinical trial data - - 0.073 0.329 - - 0.167 0.029**
Companies‘ domestic development experience with similar drugs - - 0.079 0.078* - - 0.086 0.051*
Constant −0.148 0.565 −0.098 0.706 −0.200 0.510 −0.168 0.572
aReference category, *p < 0.1, **p < 0.05, ***p < 0.01.
Fukunaga et al. SpringerPlus 2014, 3:740 Page 5 of 9
http://www.springerplus.com/content/3/1/740
Fukunaga et al. SpringerPlus 2014, 3:740 Page 6 of 9
http://www.springerplus.com/content/3/1/740null model (a model without covariates) and 0.059 for
the model including all covariates, 44% of the variance
was explained by the covariates.
We conducted post-estimation of effect size after the
regression in Model 1. Predicted effect sizes are shown
in Figure 1. The current hierarchical regression model
seems to be useful in predicting effect sizes in general,
but there are still significant variations left unexplained
by the model. Figure 1 also shows that it varies depend-
ing on drug class to what extent our model can predict
effect sizes in the real world.
Discussion
Thorough planning and implementation of clinical trials is
the key to demonstrating a test drug's therapeutic poten-
tial and to meeting regulatory requirements for new drug
approval. Success of clinical development undoubtedly
depends on the quality of the study design and implemen-
tation, and pharmaceutical companies choose critical
components of design and execution aimed at achieving
the highest possible levels of success within the relevant
budgetary and technical constraints. In this research, we
investigated possible links between components of the
study design and the effect size (i.e., the standardized out-
come of various clinical trials) and found significant asso-
ciations between them. We also investigated whether
study environment and the prior experience of drug com-
panies were associated with effect size, and some variables
yielded statistically significant associations.
Among the variables related to study design, a negative
correlation was found between the sample size and the
effect size. No consistent correlations have been reported
in other studies (Khan et al. 2004; Papakostas and Fava
2009; Yildiz et al. 2011a), and no persuasive explan-
ation was apparent for these associations. One plausibleFigure 2 Changes in the sample size by approval year.explanation for our result is that in our research targeting
only approved drugs, most drug companies successfully
achieved p values of approximately the same level (i.e.,
close to 0.05 or less) in clinical trials, which could lead to
an inverse relationship between the effect size and the
sample size. This is likely to reflect the statistical equation,
T = f (N) * g (ES) (see Methods), but it is difficult in this
model to distinguish this spurious association from sub-
stantial (i.e., causal) relationship of interest, if any. It is
interesting to note that the negative association was ob-
served even when recent increases in sample size were
controlled by the time-trend variable “approval year” in
Model 1. As Figure 2 shows, the sample size was larger
in more recent trials in our dataset (r = 0.49), and simi-
lar trends have been observed in trials submitted to the
US Food and Drug Administration (Khin et al. 2011).
The number of arms, another component of study de-
sign, was not associated with effect sizes. It was previously
reported that more number of arms resulted in greater ef-
fect sizes in placebo-controled anti-depressant trials (Khan
et al. 2004). In past decades, two-arm confirmatory trials
with an active-comparator were common in Japan (Ono
et al. 2002). Since the introduction of the International
Conference on Harmonisation (ICH) E10 guideline (The
International Conference on Harmonization 2000) and re-
cent clinical evaluation guidelines for each therapeutic
field that require a concurrent placebo control group,
however, comparative trials with both concurrent positive
comparators and a placebo arm, are expected to increase.
Our results do not necessarily reflect these changes after
the ICH E10, and caution is required when extrapolating
them.
The time-trend variable, approval year, has various im-
plications, including changes in patient populations and
background therapies, and it seems likely that various
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inclusion and exclusion criteria in recent trials to im-
prove homogeneity may yield more focused outcomes
(Rief et al. 2009). Larger effect sizes in recent trials
might also reflect drug companies' general preference to
develop more effective drug candidates than existing
drugs in response to stricter requests from the regula-
tory agency and healthcare professionals and to get
ahead of strong market competition.
Using an active comparator with the same mode of ac-
tion of the test drug seemed to yield smaller effect sizes,
with statistical purposes controlled. In such trials the
test drugs are generally less novel and innovative, thus
this result seems logical.
Regarding endpoints, clinical trials using subjective end-
points showed smaller effect sizes than those using object-
ive endpoints, although we cannot deny the possibility
that the negative coefficient for CGI-I, a categorical vari-
able, reflects some heterogeneity introduced by the differ-
ence in conversion to effect sizes. In this analysis we
defined “subjective endpoints” as those evaluated via clini-
cians' subjective interpretations of patients' responses. A
substantial difference between observer-rating scales and
self-reporting scales has been reported in some thera-
peutic fields (Rief et al. 2009; Bullens et al. 2001). This
may make it difficult to detect modest test drug/compara-
tor differences in patients' symptoms.
Primary endpoints predicted higher effect sizes than
secondary endpoints. Since our dataset consisted of suc-
cessfully approved NDAs, endpoints tagged as “primary”
were generally expected to be more efficient than sec-
ondary endpoints.
The proportion of female subjects was negatively related
to effect size. It is reported that women and men can re-
spond differently to drug treatments, particularly psycho-
logical agents (Khan et al. 2004). Some previous reports
have suggested positive associations between the male
proportion and study outcomes (Khan et al. 2004; Yildiz
et al. 2011b), which is in line with our observation. It is
still difficult to predict, however, that increasing propor-
tions of male subjects may yield better outcomes, because
the gender proportion in clinical trials seems confounded
by several factors affecting both the gender proportion
and clinical outcomes, and it is almost impossible to adjust
such potential confounders in retrospective analysis. Al-
though drug companies routinely examine possible differ-
ences in efficacy by sex in study reports, they rarely
become a focal point of discussion in the publications
such as common technical documents for NDAs and re-
view reports.
We were also interested in the possible influences of
sponsors (i.e., drug companies), and the environment of
clinical development of the drug, on effect sizes. Compan-
ies can use their previous data and experience, which varygreatly between companies, when designing and conduct-
ing trials. Regarding study environment, a previous ana-
lysis has shown that the development lag between Japan
and the US was positively associated with the probability
of transition from Phase 2 to Phase 3 trial and from Phase
3 trial to registration (Hirai et al. 2012). It has been re-
ported that the accumulation of experience also positively
affects the success rate of clinical development (Danzon
et al. 2005). We included two explanatory dummy vari-
ables in Model 2 and Model 4, "Precedent foreign clinical
trial data" and "Companies’ domestic development experi-
ence with similar drugs." The former incorporated the for-
eign clinical development experience regarding the drug
prior to Japanese clinical development. The latter was in-
cluded to explore possible roles of prior development ex-
perience of drugs in the same therapeutic class in Japan.
We considered only successful experience (i.e., experience
of NDAs approved) in this study as the explanatory vari-
able due to practical difficulties in defining experience of a
drug company and obtaining reliable data of unsuccsessful
development projects. It should be noted, however, that
both successes and failures actually consist of a company's
development experience.
The results of Model 2 in Table 2 including both phase
2 and 3 trials show that companies' domestic development
experience was positively associated with effect size, but
use of foreign clinical trial data was not. In the subgroup
analysis aiming at only phase 3 trials (Model 4 in Table 2),
however, use of foreign clinical data as well as domestic
experience had positive impact on effect size. They sug-
gested that domestic development experience might lead
to the accumulation of skills and knowledge within drug
companies. Improvement in study design, for example,
would be the key to establishing unequivocal results.
Another possibility might be ascribed to accumulated ex-
perience in domestic clinical trial professionals with whom
companies make clinical study contracts. Appropriate
planning, design, and conduct of clinical trials largely de-
pends on the skills of such professionals, and their skills
could be improved by previous experience. Our results
may support the latter possibility in that precedent devel-
opment experience in foreign countries did not necessarily
result in enhanced effect sizes in early exploratory phases.
Difficulties in extrapolating foreign clinical data and ex-
perience to the Japanese environment, probably due to the
differences of intrinsic and extrinsic factors such as med-
ical practice and therapeutic approach, might also con-
found the situation. In phase 3 confirmatory trials, drug
companies can make the most of all the preceding evi-
dence in both Japan and other countries. Even in cases
where ethnic differences have substantial impact on
clinical development, companies at this last stage of devel-
opment might be able to cope with such differences, opti-
mizing planning, design, and conduct of Japanese phase 3
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previous domestic and foreign experience.
Our study suggests that we need to be cautious about
trial design features and also drug companies’ experience
when comparing the results of clinical trials. There were
examples in which those features could have played some
role in explaining differences in trial outcomes. Re-
evaluation of a drug class termed “cerebral circulation and
metabolism improver” in Japan during the 1990s was a
historical case. Four out of five drugs in this class were
withdrawn in 1998 because they failed to establish super-
iority to placebo in clinical trials for the re-evaluation or-
dered by the Ministry of Health and Welfare (MHW)
(Hayashi et al. 1998; The Ministry of Health and Welfare.
1998). All of them had been approved based on equiva-
lence studies in comparison with calcium hopantenate.
The MHW justified its initial decisions of approval in the
late 1980s and ascribed the results to changes in the
healthcare environment such as advances in early diagno-
sis, surgical procedures, basic care, and rehabilitation. In
addition to those healthcare environment changes, differ-
ences in study design between trials for initial approval
and those for re-evaluation were noted.
Limitations
Several limitations in our study need to be considered.
First, our research focused on trials that were conducted
in Japan and submitted for Japanese NDAs. We need to
be cautious in extrapolating our current results to differ-
ent regions. The homogeneity of the study populations
of the trials has advantages, however, because it enables
us to exclude possible confounders related to heterogen-
eity of race and ethnicity, while maintaining sufficient
variety with regard to study design and developmental
phase. Second, clinical trials submitted for NDAs are
somewhat restricted in design and quality, compared to
trials that are not conducted specifically for NDAs.
Third, it should also be noted that the trials included in
this study mostly constituted successful research, in that
they were chosen on the basis of approval decisions.
Fourth, the number of placebo-controlled trials investi-
gating drugs for psychological disorders was small in our
dataset because only a small number of trials of that
kind were conducted in Japan during the observation
period. Fifth, although we know agreements between the
regulatory agency and the pharmaceutical companies
could have significant impact on study design and out-
comes, we were not able to collect data on meetings and
agreements due to difficulties in accessing in-house de-
velopment histories.
Conclusions
In conclusion, this study showed significant associations
between outcomes, study design features, and companies’experience. To further advance this research, it is neces-
sary to expand our focus and include unsuccessful trials
and unapproved drugs. Recent trends toward registry and
disclosure of clinical trial results would be helpful for
this purpose (International Federation of Pharmaceutical
Manufacturers and Associations. 2009, 2010). Further in-
vestigation is also needed to determine why these associa-
tions are apparent in clinical trials. Approaches based on
psychology and cognitive sciences may be useful to clarify
the influence of clinical investigators’ and patients’ re-
sponses to specific incentives and/or situations. Our re-
sults, in conjunction with clarification of the mechanisms
behind the observed associations, could contribute to im-
proving the quality and efficiency of clinical trials.
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Additional file 1: Table S1. List of data source.
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